|
||
Original Article |
b Tumor Immunology Program, Division of Immunogenetics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
Dept. of Medical Virology, Institute of Hygiene, University of Heidelberg, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany.49-6221-56-500349-6221-56-5525
un691gs{at}genius.embnet.dkfz-heidelberg.de
| Abstract |
|---|
|
|
|---|
Key Words: viral immune evasion apoptosis activation-induced cell death herpes simplex virus antigen presentation
Herpes simplex virus type 1 (HSV1), a member of the subfamily alphaherpesviridae, is an important neurotropic virus with a worldwide distribution. After primary infection, HSV1 becomes latent in neurons. From there it can periodically emerge to reinfect skin or other tissues, causing recurrent mucocutaneous lesions in about one third of the human population 12. In rare cases, the virus spreads within the central nervous system to cause life-threatening encephalitis. Numerous reports have demonstrated that T cells are necessary for clearing HSV1 infections and that CD8+ antiviral CTLs play a pivotal role in the elimination of most viruses. However, herpesviruses have evolved delicate strategies to evade the attack of T cells, enabling them to persist and reactivate in the host, usually without causing significant tissue damage 34.
In the course of viral infection, a population of CTL precursor cells with a TCR repertoire strongly skewed toward viral antigens is activated in the draining lymph nodes and, in the case of HSV1 infections, subsequently migrates to the site of viral replication in the epithelium 5. There, HSV virions can productively infect the antiviral CTL because HSV1 has been shown to enter activated T lymphocytes 67 after binding of the viral glycoprotein D (gD)1 to the herpesvirus entry mediator molecule (HVEM), a novel member of the TNF/nerve growth factor receptor family expressed by activated T cells 89.
HSV1, like other large DNA-containing viruses, employs multiple viral defense mechanisms that cooperate to prevent premature death of the host cell induced by a variety of intracellular and extracellular signals. The virus thereby increases the yield of viral progeny after lytic infection of its main target cells. Whether a particular viral defense mechanism is operative depends on the HSV1-infected cell type 10. It has been reported for various cell types other than CTLs that HSV proteins can block apoptosis that has been triggered as a direct response of the host cell to virus infection (cell-autonomous apoptosis) 101112. In infected human fibroblast cell lines, HSV1 has also been shown to evade attacking antiviral CTLs by preventing the transport of MHC class I molecules to the cell surface 1314 and by conferring resistance to CTL-induced antigen-dependent apoptosis 15. As viral replication in CTLs is limited, the contribution of T cell infection to the overall production of infectious HSV1 particles is marginal. This raises two important questions: Are viral defense mechanisms operative in infected T lymphocytes and, more importantly, Why are activated T cells the target of HSV1?
In this paper, we analyze the functional consequences of HSV1 infection for activated antiviral T lymphocytes and show that HSV1 removes the block by which activated CTLs protect themselves from inflicting "self injury" 1617181920. On the basis of these data, we propose a scenario of viral immune evasion in which infected antiviral T lymphocytes serve as decoy targets and kill each other (fratricide) instead of infected epithelium, the main cell type producing HSV1 virions.
Viruses and Infection.
Animals.
Irradiation.
Preparation and Stimulation of CTLs.
Purification of Murine CD8+ Lymphocytes.
Preparation and Stimulation of HSV1-reactive Lymphocytes.
Polyclonally stimulated human or mouse T lymphocytes were generated using PHA (4 µg/ml) or Con A (2.5 µg/ml), respectively, as the initial stimulus. Polyclonally activated T cells were cultured as described for HSV1-reactive T lymphocytes except that they were restimulated with PHA and Con A, respectively, in combination with uninfected irradiated stimulator cells.
Preparation and Stimulation of Human CMV-reactive T Cells.
Flow Cytometry.
Antibodies and Chimeric Proteins.
51Cr-Release Assay.
JAM Test.
Apoptosis Induction in Staphylococcus Enterotoxin B–stimulated PBMCs.
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
Cells and Media.
CV1 African green monkey kidney cells were used for propagation and titration of the virus. For studies of Kb expression and T cell activation, NIH 3T3 murine fibroblast cells or the murine mastocytoma cell line P815 and derived transfectants were employed, namely: P815-Kb expressing the gene for the heavy chain of the murine MHC class I molecule Kb 21, P815-B7 expressing the human B7.1 22, and P815-Kb-B7, which express both molecules on the cell surface 21. Human embryonic lung fibroblasts (HELs), the human lymphoblastoma cell line Jurkat, and human PBMCs isolated from units of buffy coat supplied from the University of Heidelberg blood bank were used for investigation of HSV1 infection of human cells. CV1, NIH 3T3, P815, and HEL cells were maintained in DMEM supplemented with 10% FCS, 100 IU penicillin, 100 µg/ml streptomycin, and 4 mM L-glutamine (DM medium). Transfectants of P815 cells were maintained in the same medium with a supplement of 0.4 mg/ml G418 (GIBCO BRL). Murine splenocytes and Jurkat cells were grown in RPMI 1640 supplemented with 10% heat-inactivated FCS, 100 IU penicillin, 100 µg/ml streptomycin, 4 mM glutamine, 10 mM Hepes, and 50 µM 2-ME (RP medium). Human PBMCs were propagated in the same medium, except that FCS was replaced with 10% heat-inactivated pooled human AB serum (RP-h medium).
F-US5MHC (recombinant HSV1 expressing murine β2-microglobulin and H-2Kb) and F-US5β (expressing β-galactosidase), which are identical with respect to HSV1 genes other than the transgenes, were gifts of D.C. Johnson (McMaster University, Hamilton, Ontario, Canada; 13). HSV1 strain F, from which both recombinant viruses were derived, was obtained from American Type Culture Collection (ATCC). A mutant HSV1 strain F that lacks the transporter associated with antigen processing blocking protein ICP47 (F-ICP47
) was a gift of R.L. Hendricks (University of Illinois, Chicago, IL; 23). For production of virus stock supernatant, HSV1-infected CV1 cell cultures were centrifuged at 10,000 g and then filtered with a 0.45-mm mesh filter to remove cellular debris before being pelleted for 1.5 h at 43,000 g. The viral pellet was resuspended in RPMI with 10% heat-inactivated FCS and then frozen at –80°C to give a concentrated viral stock. Frozen viral stocks were titrated using the endpoint dilution method, tested for the presence of mycoplasma using the mycoplasma detection kit (Boehringer Mannheim), and used within 4 mo of manufacture. To infect cells, virus was added to a minimal quantity of the medium appropriate for various cell types and then cultured for 1 h at 37°C. Subsequently, cells were washed three times with PBS to remove unadsorbed virus before adding fresh medium.
Kb-specific TCR (Des.TCR)-transgenic mice have been previously described 24. These transgenic animals express the rearranged TCR-
and -β genes derived from CTL clone KB5.C20, which is allospecific for the Kb antigen 25. Perforin-deficient mice 26 were provided by Dr. H. Hengartner (University of Zürich, Zürich, Switzerland). Des.TCR and perforin-deficient mice were crossed and kept under pathogen-free conditions in the animal facility of the German Cancer Research Center (Heidelberg, Germany). Female DBA/2 and C57Bl/6 mice, 4–6 wk old, were purchased from Charles River Labs. and maintained in the animal facility of the University of Heidelberg.
Gamma irradiation of 8,000 rads was found to be equally effective in preventing either cellular (P815 cells and T cell blasts) proliferation or HSV1 replication.
Mononuclear cells were isolated from murine splenocytes or human peripheral blood by separation over Ficoll-PaqueTM columns (Amersham Pharmacia Biotech). To generate murine T cell blasts by polyclonal stimulation, cells were incubated at a density of 2.5 x 106 cells/ml in RP medium with 2.5 µg/ml Con A for 2 d. As CD8+ T cells derived from Des.TCR splenocytes are >90% positive for the transgenic Kb-reactive TCR, and because Des.TCR CD4+ T cells are functionally inert, polyclonal stimulation of Des.TCR splenocytes yields Kb-reactive CD8+ T cells without further purification. For generation of CTLs specifically activated against Kb, mononuclear cells from Des.TCR-transgenic mice were incubated with irradiated P815-Kb-B7 cells at a ratio of 5:1 for 3 d in RP medium.
To generate pure activated murine CD8+ cells, Con A–stimulated mononuclear cells were initially depleted of professional APCs by incubation for 1 h on a Sephadex G-10 column (Amersham Pharmacia Biotech). For removal of B cells, the remaining nonadherent cells were incubated with anti–mouse IgG magnetic beads (Paesel & Lorei). Murine CD8+ cells were then isolated by depletion of other cell populations by passing over a CD8 negative selection column (R & D Systems, Inc.). The remaining cells were >95% CD8+ cells.
Murine mononuclear cells were prepared from the spleens of DBA/2 mice infected 6 wk before with 2.5 x 106 PFU of HSV1 strain F injected intraperitoneally in 100 µl PBS. Human mononuclear cells were prepared from the peripheral blood of HSV1-positive donors, and aliquots were frozen at –80°C, one aliquot being retained and cultured in RP-h medium with 4 µg/ml PHA for 24 h to generate activated T cells. Murine splenocytes from DBA/2 mice were activated with 2.5 µg/ml Con A. Stimulator cells were then prepared by infecting murine DBA/2 or human T cell blasts with HSV-1 F-ICP47
mutant at a multiplicity of infection (MOI) of 2 and incubating for 24 h before irradiation. Stimulator cells were then incubated with responder cells at a ratio of 1:5 in RP or RP-h medium for 72 h before half of the medium was changed and recombinant IL-2 (human or murine) added at a concentration of 40 (human) or 90 (murine) U/ml. Medium replenishment was repeated every 3 d. On day 9, cells were removed by Ficoll-PaqueTM purification and, when required, CD4+ or CD8+ cells positively selected by biotinylated anti-CD4 or anti-CD8 antibody and streptavidin-coated magnetic particles using the MACSTM system (Miltenyi Biotec). The purified HSV1-reactive T cells were incubated with fresh stimulator cells in the relevant medium with IL-2 for a further 48 h before being used in JAM assays.
For preparation of HCMV-reactive T cells, PBMCs were isolated from HCMV-positive donors and frozen. Monocytes were isolated by adhesion to tissue culture dishes, harvested, and then mixed with mononuclear cells at a ratio of 3:1 in RP-h medium supplemented with 4 µg/ml PHA. After 4 d of cultivation, the stimulated monocytes/macrophages were infected with a clinical strain of human (H)CMV (HCMV-N) at an MOI of 5, washed, and recultivated for a further 3 d before irradiation. Thereafter, these cells were used to stimulate autologous T cells essentially as described for HSV1-reactive T lymphocytes.
Standard procedures were used for flow cytometric analysis 27. In brief, for surface immunofluorescence, cells in suspension were washed once with ice-cold wash solution (PBS with 2% BSA and 0.05% sodium azide) before being resuspended with the first antibody in ice-cold blocking solution (PBS with 10% heat-inactivated FCS and 0.2% sodium azide) for 45 min. The cells were then washed in ice-cold wash solution and the staining repeated with a secondary antibody (where relevant). After the final staining step, the cells were washed in ice-cold PBS and then either resuspended in 200 µl blocking solution for measurement or fixed in 4% ice-cold paraformaldehyde for 30 min. Fixed cells were washed twice with ice-cold PBS before being stained by the TUNEL (TdT-mediated dUTP-biotin nick-end labeling) method. For TUNEL staining, fixed cells were permeabilized by ice-cold 0.1% Triton X-100 with 0.1% sodium citrate for 2 min before being washed twice with ice-cold PBS. Fixed permeabilized cells were then incubated for 1 h at 37°C with TUNEL solution (TUNEL staining kit; Boehringer Mannheim) before being washed twice with room temperature PBS. Flow cytometry was performed on a FACScanTM (Becton Dickinson) linked to an Apple Macintosh Quadra 650 using CELLQuestTM software (Becton Dickinson) for data analysis.
The following reagents were employed for FACS staining: FITC-coupled Désiré-1 as a clonotype-specific mAb to monitor the transgenic TCR 2428, and antibodies against murine CD8
(clone Ly-2), H-2Kb (clone AF6-88.5), CD95 (clones DX2 and JO2), CD95L (ligand; clone MFL3), human CD8 (clone RPA-T8), and human CD4 (clone RPA-T4), purchased from PharMingen. Antibody against viral gD was obtained from Advanced Biotechnologies, Inc. The hybridoma producing antibody W6/32, specific for MHC class I, was obtained from ATCC. Secondary antibodies and streptavidin-linked fluorochromes were obtained from Southern Biotechnology Associates. Chimeric proteins consisting of the extracellular portion of murine CD95, human TNF-related apoptosis-inducing ligand (TRAIL)R2, and human TNFR2 combined with the Fc portion of human IgG were produced by transient transfection of COS7 cells with expression plasmids encoding the various proteins in pcDNA3.9 (Invitrogen Corp.) and subsequent purification on protein G–Sepharose columns (Amersham Pharmacia Biotech).
P815 cells or CD8+ cells from DBA/2 mice were infected with HSV strain F, F-US5β, or F-US5MHC at an MOI of 10 and incubated for 4 h. Cells were then used as target cells in a 51Cr-release assay as described elsewhere 29. 51Cr was obtained from New England Nuclear.
The JAM assay 30 was performed to measure the degree of cell death. For this purpose, target cells are labeled with tritiated thymidine. If apoptosis occurs in the labeled cell population, DNA fragments will be washed through glass fiber filters during cell harvesting. In contrast, DNA from surviving target cells remains intact and will be captured by the filters. The percent cell death can be calculated by comparing the amount of [3H]thymidine bound to filters in the presence and absence of the apoptosis-inducing event. In brief, proliferating lymphocytes were pulsed overnight with tritiated thymidine at a concentration of 5 µCi/ml (New England Nuclear). Cellular debris was removed by Ficoll-PaqueTM purification, and the cells were washed twice with wash medium (RPMI with 5% heat-inactivated FCS) and counted before being used as target cells. Infected or uninfected target cells were incubated for 7 h at a density of 100,000 cells in 200 µl proliferation medium in round-bottom 96-well plates before being harvested and counted. When required, blocking antibodies or chimeric proteins were added 2 h after infection at the specified concentrations. All measurements given represent the mean of six or eight wells, and all experiments were replicated at least once on separate occasions. The highest MOI used was 10 to avoid inhibition of cytotoxic activity by HSV1 as has been previously reported 31.
PBMCs were stimulated with staphylococcal enterotoxin B (SEB) at a concentration of 1 mg/ml for 24 h. Cells were then either infected with HSV1 strain F at an MOI of 10 or mock infected and then incubated for a further 18 h with apoptosis-inducing anti-CD95 mAb. Cells were then stained for CD8 or CD4 and used in the TUNEL assay.
![]()
Results
Top
Abstract
Materials and Methods
Results
Discussion
References
HSV1 Does Not Block MHC Class I Expression on Human T Cells.
We hypothesized that infection of T lymphocytes by HSV1 could pose a severe risk for the antiviral immune response because the infected cells could present viral antigen to and thereby kill each other (fratricide). Previous studies have demonstrated that HSV1 efficiently interferes with antigen presentation in human fibroblasts due to its ability to block transport of MHC class I molecules 1314. This effect, however, can vary in different cell types. Therefore, we investigated the efficiency of HSV1's blocking of the transport of MHC class I molecules in human T cells compared with human fibroblasts. For this purpose, the human fibroblast cell line MRC-5 and activated human CD8+ lymphocytes were infected with a recombinant HSV1 strain coding for Kb, a murine MHC class I molecule (F-US5MHC). Infection of both cell types was efficient, as shown by FACSTM analysis of gD, a strongly expressed HSV1 glycoprotein (Fig. 1, bottom panels). Expression of endogenous MHC class I molecules and of virus-encoded Kb was analyzed in parallel. Human fibroblasts infected with F-US5MHC illustrated the effective viral block of MHC class I expression (Fig. 1, left): virus-encoded Kb could not be detected, and the level of endogenous MHC class I molecules was reduced by
50% 5 h after infection. By contrast, we could detect the viral Kb on the cell surfaces of human CD8+ lymphocytes (Fig. 1, right) and, in addition, we observed no inhibitory effect on the expression of endogenous MHC class I molecules 5 h after infection. These results demonstrate that, in contrast to its effect on human fibroblasts, HSV1 does not inhibit MHC class I expression by human T cells.
|
|
|
|
|
Given the importance of the CD95–CD95L interaction in HSV1-induced fratricide, we next examined the expression of CD95L and its receptor on infected CD8+ lymphocytes (Fig. 6). Interestingly, CD95L was upregulated on activated Des.TCR CD8+ T cells only after productive infection with F-US5MHC but not after infection with F-US5β, implying that triggering of the transgenic TCR by Kb resulted in higher surface expression of CD95L on activated CTLs. Supporting these data, levels of CD95L remained unchanged on HSV1-infected nontransgenic murine T cells, which are not antigen specific. Thus, HSV1 infection per se does not induce higher expression of CD95L on activated T lymphocytes 5 h after HSV1 infection. In contrast to CD95L, the expression of its receptor was not significantly altered, regardless of whether the HSV1-infected T cells recognized antigen or not. Thus, an enhanced level of CD95L expression is relevant for HSV1-induced fratricide, whereas upregulation of CD95 expression is not required. Altogether, these findings demonstrate that the CD95 system is the main effector system of HSV1-induced fratricide and, in addition, that the virus-induced increase of CD95L expression is dependent on TCR–antigen interaction.
|
|
| Discussion |
|---|
|
|
|---|
To identify the molecules involved in virus-induced fratricide, we used a transgenic mouse model of HSV1 infection. CTLs from mice expressing a Kb-reactive transgenic TCR (Des.TCR mice) were infected with a recombinant HSV1 strain coding for Kb (F-US5MHC). Blocking experiments revealed that HSV1-induced fratricide is mainly triggered by the CD95–CD95L system. Intriguingly, blocking CD95 did not totally prevent cell death, as TNF also contributed to fratricide, although to a lesser extent. In contrast, TRAIL, another member of the TNF family, was not involved. Similarly, perforin did not play a role in HSV1-induced fratricide, because T lymphocytes from Des.TCR x perforin–/– mice were as susceptible to apoptosis as T cells from Des.TCR mice. Blocking of the TCR–antigen interaction reduced fratricide to the same extent as blocking CD95. As an explanation, we found that activated CTLs from Des.TCR mice further upregulated CD95L molecules on the cell surface within a few hours after infection with Kb-encoding HSV1. Such a rapid upregulation may be due to recruitment of preformed CD95L molecules rather than to de novo synthesis 3738. This result, together with the fact that rapid cell death was not induced in human T cell lines reactive with CMV, suggests that signaling through the TCR complex after recognition of viral antigen is a prerequisite of HSV1-induced fratricide and may be the basis of viral immune evasion. In this aspect, it resembles FasL- and TNF-mediated mechanisms that induce peripheral tolerance and maintain physiological lymphocyte homeostasis 39.
It has been shown that uninfected T cells acquire a transient state of resistance to CD95-mediated signaling after activation lasting several days 32. Therefore, we have compared the susceptibility of HSV1-infected versus uninfected T lymphocytes to CD95-mediated apoptosis after SEB stimulation. As previously reported, SEB stimulates both CD4+ and CD8+ T cells 40 and confers resistance to CD95-induced apoptosis in freshly activated T cells 34. We found that subsequent HSV1 infection renders SEB-activated CD4+ and CD8+ T cells highly susceptible to induction of apoptosis through engagement of CD95 by mAbs. In contrast, abortive infection with UV-inactivated HSV1 did not confer susceptibility to CD95 signaling. This result implies that viral proteins expressed in the course of productive infection facilitate activation-induced cell death (AICD). Such a competence-to-die signal 41 has recently been demonstrated by stimulating uninfected T lymphocytes with variant peptide ligands that do not induce T cell effector functions (e.g., cytokine secretion). This does not result in upregulation of death receptors on "competent" T lymphocytes but renders them susceptible to death ligands on neighboring cells. However, the molecular basis of this phenomenon has yet to be defined, although tyrosine phosphorylation of intracellular proteins could play a role 42.
Taken together, these data suggest that apoptosis of activated T cells requires two distinct signals: one that leads to upregulation of CD95/CD95L and another that removes the block of CD95-signaling pathways at the time of CD95 triggering. AICD is triggered by repeated antigenic stimulation 434445. Accordingly, HSV1 proteins could lower the AICD threshold, the critical number of triggered TCRs during TCR–peptide–MHC interaction. It is unlikely that the viral proteins target expression or function of antiapoptotic proteins of the Bcl family like Bcl-xL or Bcl-2, because it has been reported that AICD is not prevented by these molecules 46. Alternatively, HSV1 proteins could restore the formation of the death-inducing signaling complex (DISC), which has been shown to lack FLICE (FADD-like IL-1β–converting enzyme, now referred to as caspase-8; reference 47) in freshly activated T cells that are resistant to AICD 48. This could be accomplished by downregulation of the antiapoptotic cellular FLIP (FLICE-inhibitory protein), which competes for caspase-8 recruitment to the DISC 495051525354. Thus, the viral proteins involved in facilitating AICD and the molecular basis of this effect remain to be elucidated.
Fratricide has also been implicated as an important factor in the pathogenesis of AIDS 55. T cells from HIV-1–infected individuals show upregulation of CD95/CD95L and enhanced susceptibility to CD95-mediated killing 56575859. Moreover, HIV-1–derived proteins (Tat, gp120) can enhance CD95L expression 5560. Recently, it has been demonstrated that Nef, another HIV-1 protein, forms a signaling complex with the TCR. This results in T cell activation and upregulation of CD95L expression, thereby circumventing the need for antigen recognition 60. In this way, HIV may cause global immunodeficiency, which finally results in opportunistic infections and death of the infected individuals.
We propose a different mechanism underlying fratricide in active HSV1 infections (Fig. 8). In HSV1 lesions, which usually remain focused to an area of epithelial cells, free virions can infect invading antiviral CTLs by binding to herpesvirus entry mediator (HVEM) molecule. Subsequently, viral antigens are efficiently presented on infected antiviral CTLs. Neighboring CTLs that recognize viral antigen upregulate CD95L. In addition, HSV1 lifts the block for AICD. As a consequence, infected antiviral CTLs could be better targets than infected epithelial cells, in which antigen presentation via MHC class I molecules is prevented by viral proteins. Such a cell type–specific regulation of viral defense mechanisms could turn antiviral CTLs into decoy targets, thereby enhancing local spread of the virus in epithelial cells.
|
| Acknowledgments |
|---|
. We are grateful to G. Darai and R. Kehm for technical help in preparation of virus stocks. This work was supported by grants from the Deutsche Forschungsgemeinschaft (Scho 592/1-1 and Scho 592/2-1). H. Walczak is supported by the AIDS Stipend Program of the BMBF (German Ministry of Education and Research).
Submitted: 10 June 1999
Revised: 10 August 1999
Accepted: 23 August 1999
| References |
|---|
|
|
|---|
Roizman B. & Sears A.E.. Herpes simplex viruses and their replication, Fields B.N., Knipe D.M. & Howley P.M., Virology, 1996, 2231–2295, Lippincott-Raven Publishers, Philadelphia.
Whitley R.J.. Herpes simplex viruses, Fields B.N., Knipe D.M. & Howley P.M., Virology, 1996, 2297–2342, Lippincott-Raven Publishers, Philadelphia.
Ward P.L. & Roizman B.. Evasion and obstructionthe central strategy of the interaction of human herpesviruses with host defense, Medveczky P.G., Friedman H. & Bendinelli M., Herpesviruses and Immunity, 1998, 1–32, Plenum Press, New York.
Rouse B.T. & Atherton S.S.. Immunopathology of herpesvirus infection, Medveczky P.G., Friedman H. & Bendinelli M., Herpesviruses and Immunity, 1998, 33–51, Plenum Press, New York.
Cose S.C., Jones C.M., Wallace M.E., Heath W.R. & Carbone F.R.. Antigen-specific CD8+ T cell subset distribution in lymph nodes draining the site of herpes simplex virus infection, Eur. J. Immunol., 27, 1997, 2310–2316.[Medline]
Nahmias A.J., Kibrick S. & Rosan R.C.. Viral leukocyte interrelationships. I. Multiplication of DNA virus—herpes simplex—in human leukocyte cultures, J. Immunol., 93, 1964, 69–74.
Kirchner H., Kleinicke C. & Northoff H.. Replication of herpes simplex virus in human peripheral T lymphocytes, J. Gen. Virol., 37, 1977, 647–649.
Montgomery R.I., Warner M.S., Lum B.J. & Spear P.G.. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family, Cell., 87, 1996, 427–436.[Medline]
Mauri D.N., Ebner R., Montgomery R.I., Kochel K.D., Cheung T.C., Yu G.-L., Ruben S., Murphy M., Eisenberg R.J. & Cohen G.H.. LIGHT, a new member of the TNF superfamily, and lymphotoxin
are ligands for herpesvirus entry mediator, Immunity., 8, 1998, 21–30.[Medline]
Galvan V. & Roizman B.. Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner, Proc. Natl. Acad. Sci. USA., 95, 1998, 3931–3936.
Leopardi R., van Sand C. & Roizman B.. The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the virus, Proc. Natl. Acad. Sci. USA., 94, 1997, 7891–7896.
Koyama A.H. & Miwa Y.. Suppression of apoptotic DNA-fragmentation in herpes simplex virus type 1-infected cells, J. Virol., 71, 1997, 2567–2571.[Abstract]
York I.A., Roop C., Andrews D.W., Riddell S.R., Graham F.L. & Johnson D.C.. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes, Cell., 77, 1994, 525–535.[Medline]
Hill A., Barnett B., McMichael A. & McGeoch D.. HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus type 1 and type 2, J. Immunol., 152, 1994, 2736–2741.[Abstract]
Jerome K.R., Tait J.F., Koelle D.M. & Corey L.. Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis, J. Virol., 72, 1998, 436–441.
Blakely A., Gorman K., Ostergaard H., Svoboda K., Liu C.-C., Young J.D.-E. & Clark W.R.. Resistance of cloned cytotoxic T lymphocytes to cell-mediated cytotoxicity, J. Exp. Med., 166, 1987, 1070–1083.
Verret C.R., Firmenich A.A., Kranz D.M. & Eisen H.N.. Resistance of cytotoxic T lymphocytes to the lytic effects of their toxic granules, J. Exp. Med., 166, 1987, 1536–1547.
Skinner M. & Marbrook J.. The most efficient cytotoxic T lymphocytes are the least susceptible to lysis, J. Immunol., 139, 1987, 985–987.[Medline]
Su M.W.-C., Walden P.R. & Eisen H.N.. Cognate peptide-induced destruction of CD8+ cytotoxic T lymphocytes is due to fratricide, J. Immunol., 151, 1993, 658–667.[Abstract]
Müller C. & Tschopp J.. Resistance of CTL to perforin-mediated lysis. Evidence for a lymphocyte membrane protein interacting with perforin, J. Immunol., 153, 1994, 2470–2478.[Abstract]
Müller A., Schmitt L., Raftery M. & Schönrich G.. Paralysis of B7 co-stimulation through the effect of viral IL-10 on T cells as a mechanism of local tolerance induction, Eur. J. Immunol., 28, 1998, 3488–3498.[Medline]
Azuma M., Cayabyab M., Buck D., Phillips J.H. & Lanier L.L.. CD28 interaction with B7 costimulates primary allogeneic proliferative response and cytotoxicity mediated by small, resting T lymphocytes, J. Exp. Med., 175, 1992, 353–360.
Goldsmith K., Chen W., Johnson D.C. & Hendricks R.L.. Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response, J. Exp. Med., 187, 1998, 341–348.
Schönrich G., Kalinke U., Momburg F., Malissen M., Schmitt-Verhulst A.-M., Malissen B., Hämmerling G.J. & Arnold B.. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction, Cell., 65, 1991, 293–304.[Medline]
Albert F., Buferne M., Boyer C. & Schmitt-Verhulst A.-M.. Interaction between MHC-encoded-products and cloned T cells. I. Fine specificity of induction of proliferation and lysis, Immunogenetics., 76, 1982, 533–549.
Kägi D., Ledermann B., Bürki K., Seiler P., Odermatt B., Olsen K.J., Podack E.R., Zinkernagel R.M. & Hengartner H.. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice, Nature., 369, 1994, 31–37.[Medline]
Otten, G., and W.M. Yokoyama. 1992. Flow cytometry analysis using the Becton Dickinson FACScan. In Current Protocols in Immunology. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, editors. Greene Publishing and Wiley-Interscience, New York. 5.4.1–5.4.19.
Hua C., Boyer C., Buferne M. & Schmitt-Verhulst A.-M.. Monoclonal antibodies against an H-2Kb-specific cytotoxic T cell clone detect several clone-specific molecules, J. Immunol., 136, 1986, 1937–1944.[Abstract]
Wunderlich, J., G. Shearer, and A. Livingstone. 1997. Induction and measurement of cytotoxic T lymphocyte activity. In Current Protocols in Immunology. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, editors. John Wiley & Sons, Inc., New York. 3.11.1–3.11.20.
Matzinger P.. The JAM test. A simple assay for DNA fragmentation and cell death, J. Immunol. Methods., 145, 1991, 185–192.[Medline]
Possavad C.M., Newton J.J. & Rosenthal K.L.. Infection and inhibition of human cytotoxic T lymphocytes by herpes simplex virus, J. Virol., 68, 1994, 4072–4074.
Klas C., Debatin K.-M., Jonker R.R. & Krammer P.H.. Activation interferes with the APO-1 pathway in mature human T cells, Int. Immunol., 5, 1993, 625–630.
Shresta S., Pham C.T.N., Thomas D.A., Graubert T.A. & Ley T.J.. How do cytotoxic lymphocytes kill their targets?, Curr. Opin. Immunol., 10, 1998, 581–587.[Medline]
McLeod J.D., Walker L.S.K., Patel Y.I., Boulougouris G. & Samson D.M.. Activation of human T cells with superantigen (staphylococcal enterotoxin B) and CD28 confers resistance to apoptosis via CD95, J. Immunol., 160, 1998, 2072–2079.
Ahn K., Meyer T.H., Uebel S., Sempé P., Djaballah H., Yang Y., Peterson P.A., Früh K. & Tampé R.. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus protein ICP47, EMBO (Eur. Mol. Biol. Organ.) J., 15, 1996, 3247–3255.[Medline]
Tomazin R., Hill A.B., Jugovic P., York I., van Endert P., Ploegh H., Andrews D.W. & Johnson D.C.. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP, EMBO (Eur. Mol. Biol. Organ.) J., 15, 1996, 3256–3266.[Medline]
Li J., Rosen D., Ronen D., Behrens C.K., Krammer P.H., Clark W.R. & Berke G.. The regulation of CD95L expression and function in CTL, J. Immunol., 161, 1998, 3943–3949.
Bossi G. & Griffiths G.M.. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells, Nat. Med., 5, 1999, 90–96.[Medline]
Van Parijs L. & Abbas A.K.. Homeostasis and self-tolerance in the immune systemturning lymphocytes off, Science., 280, 1998, 243–248.
Herrmann T., Baschieri S., Lees R.K. & MacDonald H.R.. In vivo responses of CD4+ and CD8+ cells to bacterial superantigens, Eur. J. Immunol., 22, 1992, 1935–1938.[Medline]
Hornung F., Zheng L.X. & Lenardo M.J.. Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes, J. Immunol., 159, 1997, 3816–3822.[Abstract]
Combadière B., Reis e Sousa C., Trageser C., Zheng L.-X., Kim C.R. & Lenardo M.J.. Differential TCR signaling regulates apoptosis and immunopathology during antigen responses in vivo, Immunity., 9, 1998, 305–313.[Medline]
Dhein J., Walczak H., Baeumler C., Debatin K.M. & Krammer P.H.. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95), Nature., 373, 1995, 438–441.[Medline]
Brunner T., Mogil R.J., LaFace D., Yoo N.J., Mahboubi A., Echeverri F., Martin S.J., Force W.R., Lynch D.H. & Ware C.F.. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation induced apoptosis in T-cell hybridomas, Nature., 373, 1995, 441–444.[Medline]
Ju S.-T., Panka D.J., Cui H., Ettinger R., El-Khatib M., Sherr D.H., Stanger B.Z. & Marshak-Rothstein A.. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation, Nature., 373, 1995, 444–448.[Medline]
Van Parijs L., Ibraghimov A. & Abbas A.K.. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance, Immunity., 4, 1996, 321–328.[Medline]
Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W. & Yuan J.. Human ICE/CED-3 protease nomenclature, Cell., 87, 1996, 171, .[Medline]
Peter M.E., Kischkel F.C., Scheuerpflug C.G., Medema J.P., Debatin K.-M. & Krammer P.H.. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death inducing signaling complex, Eur. J. Immunol., 27, 1997, 1207–1212.[Medline]
Hu S., Vincenz C., Buller M. & Dixit V.M.. A novel family of viral death effector domain-containing molecules that inhibit both CD95- and tumor necrosis factor receptor-1-induced apoptosis, J. Biol. Chem., 272, 1997, 9621–9624.
Thome M., Schneider P., Hofmann K., Fickenscher H., Meinl E., Neipel F., Mattmann C., Burns K., Bodmer J.L. & Schroter M.. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors, Nature., 386, 1997, 517–521.[Medline]
Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodme J.L., Schroeter M., Burns K. & Mattmann C.. Inhibition of death receptor signals by cellular FLIP, Nature., 388, 1997, 190–195.[Medline]
Goltsev Y.V., Kovalenko A.V., Arnold E., Varvolomeev E.E., Brodianskii V.M. & Wallach D.. CASH, a novel caspase homologue with death effector domains, J. Biol. Chem., 272, 1997, 19641–19644.
Hu S., Vincenz C., Ni J., Gentz R. & Dixit V.M.. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD95-induced apoptosis, J. Biol. Chem., 272, 1997, 17255–17257.
Srinivasula S.M., Ahmad M., Ottilie S., Bullrich F., Banks S., Wang Y., Fernandes Alnemri T., Croce C.M., Litwack G. & Tomaselli K.J.. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis, J. Biol. Chem., 272, 1997, 18542–18545.
Westendorp M.O., Frank R., Ochsenbauer C., Stricker K., Dhein J., Walczak H., Debatin K.M. & Krammer P.H.. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120, Nature., 375, 1995, 497–500.[Medline]
Debatin K.M., Fahrig-Faissner A., Enenkel-Stoodt S., Kreuz W., Benner A. & Krammer P.H.. High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children, Blood., 83, 1994, 3101–3103.
Katsikis P.D., Wunderlich E.S., Smith C.A., Herzenberg L.A. & Herzenberg L.A.. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus–infected individuals, J. Exp. Med., 181, 1995, 2029–2036.
McCloskey T.W., Oyaizu N., Kaplan M. & Pahwa S.. Expression of the Fas antigen in patients infected with human immunodeficiency virus, Cytometry., 22, 1995, 111–114.[Medline]
Badley A.D., Dockrell D.H., Algeciras A., Ziesmer S., Landay A., Lederman M.M., Connick E., Kessler H., Kuritzkes D. & Lynch D.H.. In vivo analysis of Fas/FasL interactions in HIV-infected patients, J. Clin. Invest., 102, 1998, 79–87.[Medline]
Xu X.-N., Laffert B., Screaton G.R., Kraft M., Wolf D., Kolanus W., Mongkolsapay J., McMichael A.J. & Baur A.S.. Induction of Fas ligand expression by HIV involves the interaction of nef with the T cell receptor
chain, J. Exp. Med., 189, 1999, 1489–1496.
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|